
    
      The study is an open label, randomized, crossover, 2-period study in 30 male/female patients
      with primary CNS malignancies. Patients will receive, under fasting conditions, 200 mg/m² of
      Temozolomide Oral Suspension (Ped-TMZ) or Temodal®, as single oral administration in 2
      different study periods depending on the randomization, with no wash out period between
      administrations.
    
  